We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Motif Bio Plc | LSE:MTFB | London | Ordinary Share | GB00BVVT4H71 | ORD 0.01P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.50 | 0.40 | 0.55 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMMTFB
Motif Bio PLC
08 February 2017
8 February 2017
Motif Bio plc
("Motif" or the "Company")
Investor Presentation
Motif Bio plc (AIM: MTFB) the clinical stage biopharmaceutical company specialising in developing novel antibiotics, announces it will be holding a presentation for investors on Tuesday 21 February 2017.
The event will be held at the Black Bar, upstairs at Rocket Bar, 6 Adams Court, Old Broad Street, London, EC2N 1DX from 4.30pm for a 4.45pm start.
A presentation will be given by the Chief Executive Officer, Graham Lumsden and the newly appointed Chief Financial Officer, Robert Dickey IV, and will cover an overview of the Company and the progress with the REVIVE-1 clinical trial of iclaprim compared to vancomycin in patients with acute bacterial skin and skin structure infections. This will be followed by an opportunity to network over drinks and canapés.
To register for the event, please contact motifbio@walbrookpr.com or call the Walbrook PR team below.
For further information please contact:
Walbrook PR Ltd. (FINANCIAL +44 (0)20 7933 8780 or motifbio@walbrookpr.com PR & IR) Mike Wort / Lianne Cawthorne
Notes to Editors:
Motif Bio is a clinical-stage biopharmaceutical company, engaged in the research and development of novel antibiotics designed to be effective against serious and life-threatening infections in hospitalised patients caused by multi-drug resistant bacteria. Our lead product candidate, iclaprim, is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (VABP), which is often caused by MRSA (methicillin resistant Staphylococcus aureus). We are currently enrolling and dosing patients in two global Phase 3 clinical trials (Revive 1 and Revive 2) with an intravenous formulation of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-1 is expected in the second quarter of 2017 and REVIVE-2 is on track for data readout in the second half of 2017.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALLFESFEITIID
(END) Dow Jones Newswires
February 08, 2017 09:57 ET (14:57 GMT)
1 Year Motif Bio Chart |
1 Month Motif Bio Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
